4//SEC Filing
Gilbert Richard P. 4
Accession 0001209191-09-042277
CIK 0000815838other
Filed
Aug 26, 8:00 PM ET
Accepted
Aug 27, 3:57 PM ET
Size
17.1 KB
Accession
0001209191-09-042277
Insider Transaction Report
Form 4
Gilbert Richard P.
Vice President - Operations
Transactions
- Disposition to Issuer
Stock Appreciation Rights
2009-08-27−19,908→ 0 totalExercise: $22.83Exp: 2013-11-13→ Common Stock ($.0001 par value) (19,908 underlying) - Disposition to Issuer
Stock Appreciation Right
2009-08-27−29,806→ 0 totalExercise: $14.54Exp: 2014-11-12→ Common Stock ($.0001 par value) (29,806 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2009-08-27−23,191→ 0 totalExercise: $13.68Exp: 2012-11-14→ Common Stock ($.0001 par value) (23,191 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2009-08-27−30,000→ 0 totalExercise: $16.35Exp: 2011-12-05→ Common Stock ($.0001 par value) (30,000 underlying) - Disposition to Issuer
Stock Appreciation Right
2009-08-27−66,921→ 0 totalExercise: $11.09Exp: 2015-11-17→ Common Stock ($.0001 par value) (66,921 underlying)
Footnotes (6)
- [F1]Represents stock options cancelled at the Effective Time (as defined in the Merger Agreement), pursuant to the terms of an Agreement and Plan of Merger among the Issuer, Hisamitsu Pharmaceutical Co., Inc. ("Hisamitsu") and certain subsidiaries of Hisamitsu, dated as of July 14, 2009 (the "Merger Agreement"), in exchange for a cash payment of $4,500, representing an amount equal to the number of shares of Issuer's common stock underlying such stock options multiplied by the tender offer price of $16.50 per share, less the aggregate exercise price of the stock options.
- [F2]Represents stock options cancelled at the Effective Time, pursuant to the Merger Agreement, in exchange for a cash payment of $65,398.62, representing an amount equal to the number of shares of Issuer's common stock underlying such stock options multiplied by the tender offer price of $16.50 per share, less the aggregate exercise price of the stock options.
- [F3]Represents stock appreciation rights cancelled at the Effective Time, pursuant to the Merger Agreement. The reporting person did not receive any cash payment therefor as the exercise price exceeded the tender offer price of $16.50.
- [F4]Represents stock appreciation rights cancelled at the Effective Time, pursuant to the Merger Agreement, in exchange for a cash payment of $58,419.76, representing an amount equal to the number of shares of Issuer's common stock underlying such stock appreciation rights multiplied by the tender offer price of $16.50 per share, less the aggregate exercise price of the stock appreciation rights.
- [F5]Represents stock appreciation rights cancelled at the Effective Time, pursuant to the Merger Agreement, in exchange for a cash payment of $362,042.61, representing an amount equal to the number of shares of Issuer's common stock underlying such stock appreciation rights multiplied by the tender offer price of $16.50 per share, less the aggregate exercise price of the stock appreciation rights.
- [F6]Due to a clerical rounding error, the previous Form 4 reporting this grant of stock appreciation rights incorrectly overstated by one each of (i) the number of stock appreciation rights granted, and (ii) the number of shares of common stock underlying such stock appreciation rights.
Documents
Issuer
NOVEN PHARMACEUTICALS INC
CIK 0000815838
Entity typeother
Related Parties
1- filerCIK 0001437132
Filing Metadata
- Form type
- 4
- Filed
- Aug 26, 8:00 PM ET
- Accepted
- Aug 27, 3:57 PM ET
- Size
- 17.1 KB